Sector: Financials | Industry: Closed End Funds |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1900 Market Street, Suite 200 PHILADELPHIA PA 19103 |
Tel: | N/A |
Website: | https://www.teklacap.com/funds/hql/fund/fund-information |
IR: | See website |
Key People | ||
Daniel R. Omstead President, Trustee | Laura Woodward Chief Compliance Officer, Treasurer, Secretary |
Business Overview |
abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc. |
Financial Overview |
For the fiscal year ended 30 September 2023, Abrdn Life Sciences Investors revenues increased 16% to $3.5M. Net income totaled $22.4M vs. loss of $104.6M. Revenues reflect Interest and other income increase from $50K to $204K, Dividend income increase of 1% to $2.9M. Net Income reflects Investments in affiliated issuers decrease of 88% to $15.3M (expense), Net realized gain increase of 43% to $35.9M (income). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $336.04M as of Sep 30, 2023 |
Annual revenue (TTM): | $3.50M as of Sep 30, 2023 |
EBITDA (TTM): | -$2.18M as of Sep 30, 2023 |
Net annual income (TTM): | $22.35M as of Sep 30, 2023 |
Free cash flow (TTM): | N/A |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 26,791,197 as of Sep 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |